Skip to content
10-Q

Quarterly Report

IRADIMED CORP IRMD

0001628280-26-029325

← back to feed
Filed
May 1, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 12.78M sh
Shares Diluted Q1 2026 · Mar 31, 2026 12.87M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 12.83M sh
Dividends Paid Q1 2026 · Mar 31, 2026 $2.56M
Dividends Paid restated Q1 2026 · Mar 31, 2025 $2.16M
Capex Q1 2026 · Mar 31, 2026 $403K
Capex restated Q1 2026 · Mar 31, 2025 $3.7M
Operating Cash Flow Q1 2026 · Mar 31, 2026 $8.29M
Operating Cash Flow restated Q1 2026 · Mar 31, 2025 $4.29M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $56.37M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $51.16M
Stockholders Equity Q1 2026 · Mar 31, 2026 $98.51M
Stockholders Equity Q1 2026 · Dec 31, 2025 $94.62M
Stockholders Equity restated Q1 2026 · Mar 31, 2025 $90.05M
Stockholders Equity restated Q1 2026 · Dec 31, 2024 $86.82M
Current Liabilities Q1 2026 · Mar 31, 2026 $12.12M
Current Liabilities Q1 2026 · Dec 31, 2025 $10.18M
Total Liabilities Q1 2026 · Mar 31, 2026 $15.88M
Total Liabilities Q1 2026 · Dec 31, 2025 $14.16M
Current Assets Q1 2026 · Mar 31, 2026 $86.42M
Current Assets Q1 2026 · Dec 31, 2025 $81.2M
Total Assets Q1 2026 · Mar 31, 2026 $114.39M
Total Assets Q1 2026 · Dec 31, 2025 $108.78M
Eps Diluted Q1 2026 · Mar 31, 2026 $0.45
Eps Diluted Q1 2026 · Mar 31, 2025 $0.37
Eps Basic Q1 2026 · Mar 31, 2026 $0.46
Eps Basic Q1 2026 · Mar 31, 2025 $0.37
Sga Expense Q1 2026 · Mar 31, 2026 $4.57M
Sga Expense restated Q1 2026 · Mar 31, 2025 $4.61M
Rd Expense Q1 2026 · Mar 31, 2026 $956K
Rd Expense restated Q1 2026 · Mar 31, 2025 $624K
Net Income Q1 2026 · Mar 31, 2026 $5.82M
Net Income restated Q1 2026 · Mar 31, 2025 $4.69M
Operating Income Q1 2026 · Mar 31, 2026 $7.24M
Operating Income restated Q1 2026 · Mar 31, 2025 $5.43M
Gross Profit Q1 2026 · Mar 31, 2026 $16.81M
Gross Profit restated Q1 2026 · Mar 31, 2025 $14.84M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $5.17M
Cost Of Revenue restated Q1 2026 · Mar 31, 2025 $4.67M
Revenue Q1 2026 · Mar 31, 2026 $21.98M
Revenue restated Q1 2026 · Mar 31, 2025 $19.51M